Andrew Mcbain

Andrew Mcbain is a Professor of Microbiology at the University of Manchester, specializing in bacterial physiology, biofilm dynamics, and human microbiome research. He leads a research team supported by grants from research councils and industry, focusing on antimicrobial resistance, microbial community modeling, and host-microbe interactions. His work contributes to sustainable development goals related to health and environmental sustainability.

• Education: PhD in Medical Microbiology (University of Cambridge, 1997); BSc in Microbiology (University of Liverpool, 1993).
• Teaching: Courses include The Public (Year 2), Medicines into Practice, and Drug Development Workshop.

Research interests include in vitro modeling of microbial communities (e.g., biofilm reactors), probiotic applications, and clinical microbiota dynamics. He has supervised 39 PhD/MD students and collaborates with experts like Prof. Catherine O'Neill and Prof. Sheena Cruickshank.

Key projects include Developing New Biocides (2019–2022) and Maternal Obesity and Extracellular Vesicles (2024–2027). His work has led to the creation of SkinBiotherapeutics PLC, advancing probiotic technologies for skin health.

• Grants: Includes funding from the Medical Research Council and industry partnerships.
• Lab Affiliations: Lydia Becker Institute and Christabel Pankhurst Institute at Manchester.

Publications span over 213 articles, with recent focus on microbiome profiling, antimicrobial peptides, and light-based therapies. Awards include the W H Pierce Prize (2005) from the Society for Applied Microbiology.